Bioactive Compounds and Therapeutic Applications of Dracaena Species

Dracaena species, long valued for their red resin known as dragon’s blood, are a rich source of bioactive metabolites including flavonoids, stilbenoids, phenolic compounds, saponins and steroids. These secondary metabolites exhibit a broad spectrum of pharmacological activities, notably anti-inflammatory, antioxidant, antimicrobial, analgesic and antitumour effects. Mechanistic studies have demonstrated that Dracaena extracts modulate key cellular pathways—such as the PI3K-AKT axis, NF-κB signalling and mitochondrial apoptotic cascades—to inhibit malignant cell proliferation, reduce oxidative stress and suppress inflammatory mediators. In cardiovascular contexts, dragon’s blood constituents prevent thrombosis, enhance endothelial function and alleviate myocardial injury through anti-fibrotic and vasodilatory actions. Geographical and species-specific variations in resin composition have been revealed by metabolomic profiling, underscoring the importance of standardising raw material sources. Advances in endophyte research further suggest that fungal partners influence resin biosynthesis and may be harnessed to optimise yields. Collectively, the growing corpus of phytochemical, molecular and translational investigations positions Dracaena-derived compounds as promising leads for the development of novel therapeutics across oncology, cardiology and infectious disease.

Research from Nature Portfolio

Recent network-pharmacology and experimental studies have elucidated the mechanisms by which dragon’s blood resin inhibits breast cancer cell growth. A systematic analysis identified over 100 active flavone compounds targeting key molecules such as AKT1, ESR1 and CASP3. Pathway enrichment highlighted the PI3K-AKT cascade as central to the resin’s antitumour effects. Molecular docking confirmed strong binding of sanguis draconis flavones to these targets, and subsequent cell-culture assays demonstrated that the flavone fraction arrests MCF-7 cells in the G1 phase, downregulates anti-apoptotic Bcl-2 family proteins and activates caspases, thereby inducing apoptosis. This integrative approach provides a robust mechanistic framework linking specific resin constituents to therapeutic outcomes and offers a template for advancing Dracaena-based interventions in oncology.

Bioactive Compounds and Therapeutic Applications of Dracaena Species publication trend

The graph below shows the total number of articles in bioactive compounds and therapeutic applications of dracaena species across all publications each year (not limited to Nature Index journals).

Technical terms

Flavonoids: Polyphenolic compounds with a common C6–C3–C6 skeleton, known for antioxidant and anti-inflammatory properties.

Stilbenoids: Phenolic metabolites derived from stilbene, exhibiting antimicrobial, antioxidant and anticancer activities.

Dragon’s blood: A red resin exudate from Dracaena species, rich in flavonoids and phenolics, used traditionally in medicine.

PI3K-AKT pathway: A signalling cascade involved in cell survival, proliferation and metabolism, often dysregulated in cancer.

Network pharmacology: A computational framework integrating bioactive compounds, targets and pathways to predict therapeutic mechanisms.

References

1. Metabolomics and quantitative analysis to determine differences in the geographical origins and species of Chinese dragon’s blood. Frontiers in Plant Science (2024).
2. Potential therapeutic mechanisms of Draconis Resina in cardiovascular diseases-a narrative review. Frontiers in Pharmacology (2025).
3. Spatiotemporal composition and diversity of endophyte communities in Dracaena cambodiana on Hainan Island. Frontiers in Microbiology (2025).
4. Exploring the Anticancer Potential of Traditional Thai Medicinal Plants: A Focus on Dracaena loureiri and Its Effects on Non-Small-Cell Lung Cancer. Plants (2024).
5. The inhibitory effect and mechanism of Resina Draconis on the proliferation of MCF-7 breast cancer cells: a network pharmacology-based analysis. Scientific Reports (2023).
6. Flavonoids and Stilbenoids of the Genera Dracaena and Sansevieria: Structures and Bioactivities. Molecules (2020).
7. A Systematic Review of the Botanical, Phytochemical and Pharmacological Profile of Dracaena cochinchinensis, a Plant Source of the Ethnomedicine “Dragon’s Blood”. Molecules (2014).
8. Bioprotective properties of Dragon's blood resin: In vitro evaluation of antioxidant activity and antimicrobial activity. BMC Complementary Medicine and Therapies (2011).
9. Cell Cycle Arrest and Apoptosis Induction via Modulation of Mitochondrial Integrity by Bcl‐2 Family Members and Caspase Dependence in Dracaena cinnabari‐Treated H400 Human Oral Squamous Cell Carcinoma. BioMed Research International (2016).